You are here

HIFU for Prostate Cancer Now Available at Chesapeake Urology

CHARLOTTE, N.C., Jan. 23, 2018 (GLOBE NEWSWIRE) -- HIFU Prostate Services, LLC, the leading provider of HIFU technology to physician practices in the United States, is excited to announce a partnership with Chesapeake Urology, the largest urology practice in Maryland and the Mid-Atlantic region. This partnership will bring HIFU as a treatment option for localized prostate cancer with the Sonablate to men in the area.

“We are thrilled to offer this innovative treatment for our patients. Chesapeake Urology strives to be a leader in prostate cancer care, and men will now have access to this non-invasive, outpatient treatment,” said Anup Vora, MD, director of prostate cancer focal and ablative therapy at Chesapeake Urology.

HIFU precisely focuses ultrasound energy to rapidly heat and destroy tissue in the prostate. Due to its accuracy and precision, areas around the prostate are undamaged which greatly reduces the risk of side effects such as urinary incontinence and erectile dysfunction.

Last summer, a Medicare code was issued by the Centers for Medicare and Medicaid Services that may help some patients cover part of the cost of the HIFU procedure. Additional information about reimbursement may be found at https://www.hifuprostateservices.com/reimbursement.

“We are delighted to have partial Medicare coverage for this procedure. This will enable greater opportunity for patients to have this one-time procedure with its limited side effect profile,” said Dr. Vora.

As a one-time, outpatient procedure, HIFU allows patients to return home the same day as their procedure and return to their normal lifestyle within a few days.
HIFU may be repeated, if necessary, and can be used to treat patients that have failed radiation therapy. It does not preclude any future treatments including surgery or radiation.

“Chesapeake Urology is widely considered one of the leading LUGPA groups in the U.S. and we are excited to partner with them and their network of physicians,” said John Linn, chief executive officer, HIFU Prostate Services.

About HIFU Prostate Services, LLC
HIFU Prostate Services was founded to provide men access to a less invasive treatment option for prostate cancer that has the ability to eliminate cancer and preserve patient quality of life. Our mission is to deliver the highest quality of care, support, and technology to the patient and to the urology community for the treatment of localized prostate cancer using Sonablate® HIFU. The company is headquartered in Charlotte, NC and with locations in 14 cities throughout the US. Learn more at http://www.hifuprostateservices.com.

About Chesapeake Urology
Chesapeake Urology is the largest urology practice in Maryland and the Mid-Atlantic region, providing a comprehensive array of urologic services to patients. In fact, individuals and families come to Chesapeake Urology from Maryland, Virginia, Pennsylvania, Delaware, Washington DC and all over the United States to receive the most advanced treatment from our team of world class urologists.

Chesapeake Urology, including its Urological Consultants division, operates 25 medical offices and 17 AAAHC-certified ambulatory surgery centers in Baltimore, Harford, Howard, Carroll, Montgomery, Prince George’s, Charles and Anne Arundel counties and in Baltimore City, and has a staff of more than 725 including 87 physicians, 80 which are urologists. Learn more at http://www.chesapeakeurology.com.

Media Contact:
John Linn (704) 248-7562

Tuesday, January 23, 2018 - 10:00

More Headlines

COMPASS Trial Shows 24% Reduction in Major CV Events
Only 18.7% of Patients Treated Had Uveitis Recurrence
Protein Organizes and Stores DNA for B Cells in Methodical Fashion
Patients’ Bodies Most Common Source of Hospital-Acquired Bloodstream Infections
Growing opioid crisis fueling suicide increase according to study
Vaccine Prevents Some Cancers, Diseases Caused by 9 HPV Types
In Future, Providers May Screen for APOE4 Before Treatment 
MIT Professor Working to Produce Thousands of Drugs on Demand
Agency Scrutinizes Attempts to Block Generics